KurKestutis / Shutterstock.com
Biotechnology company Thermo Fisher Scientific said its potential merger with genomics company Affymetrix is its preferred option to another potential deal.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Thermo Fisher, Affymetrix, mergers and acquisitions, biotechnology, Origin Technologies, superior proposal, due diligence, Frank Witney, Marc Casper,